跳转至内容
Merck
CN

494429

二甲基亚砜

biotech. grade, 99.8%

别名:

DMSO, 甲基亚砜

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

线性分子式:
(CH3)2SO
化学文摘社编号:
分子量:
78.13
EC Number:
200-664-3
UNSPSC Code:
12191502
PubChem Substance ID:
Beilstein/REAXYS Number:
506008
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


grade

biotech. grade

vapor density

2.7 (vs air)

vapor pressure

0.42 mmHg ( 20 °C)

assay

99.8%

autoignition temp.

573 °F

expl. lim.

42 %, 63 °F

impurities

<0.005% water

evapn. residue

<0.0005%

refractive index

n20/D 1.479 (lit.)

bp

189 °C (lit.)

mp

16-19 °C (lit.)

density

1.10 g/mL (lit.)

λ

H2O reference

UV absorption

λ: 270 nm Amax: 1.00, λ: 280 nm Amax: 0.30, λ: 295 nm Amax: 0.10, λ: 350-400 nm Amax: 0.01

SMILES string

CS(C)=O

InChI

1S/C2H6OS/c1-4(2)3/h1-2H3

InChI key

IAZDPXIOMUYVGZ-UHFFFAOYSA-N

Packaging

Disclaimer

在室温下容易过冷并缓慢重融。 固化产品可以通过加热至室温来重新液化,而不会损害产品。


Still not finding the right product?

Explore all of our products under 二甲基亚砜


存储类别

10 - Combustible liquids

wgk

WGK 1

flash_point_f

188.6 °F - closed cup

flash_point_c

87 °C - closed cup

法规信息

新产品

此项目有



历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库



Claudia C Faria et al.
Cancer research, 75(1), 134-146 (2014-11-14)
Medulloblastoma is the most common malignant pediatric brain tumor, with metastases present at diagnosis conferring a poor prognosis. Mechanisms of dissemination are poorly understood and metastatic lesions are genetically divergent from the matched primary tumor. Effective and less toxic therapies
Phillip McDonagh et al.
Veterinary microbiology, 174(3-4), 438-447 (2014-12-04)
Feline infectious peritonitis (FIP), a feline coronavirus (FCoV) induced disease, is almost invariably fatal with median life expectancy measured in days. Current treatment options are, at best, palliative. The objectives of this study were to evaluate a panel of nineteen
A Hillarp et al.
Journal of thrombosis and haemostasis : JTH, 12(9), 1545-1553 (2014-06-27)
Apixaban is an oral direct factor Xa inhibitor developed for the prophylaxis and treatment of thromboembolic disorders. Laboratory monitoring is not necessary, but the effects on common coagulation reagents and assays constitute clinically valuable information. To investigate the effects of apixaban